Clinical Trials

240 enrolled 20 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07566156 2026-05-11

EV-309

Phase 3 Recruiting

390 enrolled

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06211764 2026-05-08

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-05-08

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04241185 2026-05-01

MK-3475-992

520 enrolled

Urinary Bladder Neoplasms

NCT06774131 2026-04-29

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

70 enrolled

Carcinoma, Transitional Cell

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06331299 2026-01-15

UTOPIA

99 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05494411 2025-02-28

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Available

Carcinoma, Transitional Cell

NCT05874921 2025-02-28

uTRACT

Recruiting

400 enrolled

Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04688931 2024-06-06

ATLAS

282 enrolled 29 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03558503 2022-09-16

OPTIMA II

Phase 2 Completed

63 enrolled 27 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02316171 2022-07-27

CANON

Phase 1 Completed

16 enrolled 8 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00318643 2021-10-29

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Phase 1/2 Completed

27 enrolled 14 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01438112 2021-04-14

BOND

Phase 2/3 Terminated

22 enrolled

71 enrolled 16 charts 1 FDA

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT02793128 2020-12-22

Olympus

Phase 3 Completed

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

Phase 3 Withdrawn

Carcinoma, Carcinoma, Transitional Cell

NCT03335059 2020-04-15

RITE-USA

5 enrolled

Urinary Bladder Neoplasms, Disease

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

36 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01200992 2017-08-24

EMBARC-RF

84 enrolled 7 charts